Inspira Technologies Reports Second Quarter 2023 Financial Results As of

Inspira Technologies Reports Second

Quarter 2023 Financial Results

As of June 30, 2023, the Company had $8.9

million in cash, cash equivalents and short-term bank deposits.

Ra'anana, Israel, August 10, 2023 -

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira"), a company aiming

to revolutionize acute respiratory care, announced today its financial results for the second quarter ended June 30, 2023.

ART100 - We are focused on the final stages

of the development of the INSPIRA ART100, which is planned to be submitted to the U.S. Food and Drug Administration (the "FDA")

clearance via the 510(k) pathway. We believe that the potential completion of the INSPIRA ART100 illustrates and validates our capability

to take a product from research to a full regulatory submission and illustrates the potential of our intellectual property. The INSPIRA

ART100 is designed for life support, providing pulmonary and cardiac support. The Company is preparing for the unveiling of the INSPIRA

ART100 at the world's largest Extracorporeal Life Support Organization (ELSO) conference, the 34th Annual ELSO Conference in Seattle,

Washington, which will be held between September 28 and October 1, 2023.

- We continue to expend company resources towards the development of the INSPIRA ART500 and integrated artificial intelligence ("AI")

and blood sensor technology. The Company is awaiting potential future grants of patents in the U.S. for the INSPIRA ART500 technologies.

The INSPIRA ART500 is

a potentially disruptive, paradigm-shifting solution, offering a potentially new treatment category that uniquely utilizes small volumes

of blood to increase oxygen saturation levels in minutes. To empower awake patients to breathe without lungs, the Company intends to integrate

advanced hemodynamic sensor technologies with AI-powered real-time analytics to support significantly improving patient outcomes. In today's

fast-paced healthcare environment, limited patient interaction time and a lack of real-time data can lead to overlooking subtle changes

in the patient's condition, which could negatively impact clinical outcomes. INSPIRA AI will usher in a new era of hyper-personalization

acute respiratory care, delivering real-time insights and alerts to support physician decision-making to support timely clinical intervention

and enhance the quality of care.

pleased with our progress in the second quarter of 2023," said Dagi Ben-Noon, Chief Executive Officer of Inspira. "We are

dedicated to delivering value to both patients who potentially may need our future products and our shareholders alike. We remain committed

to driving innovation, expanding our technological and product development to bring new needed technologies to the medical device market."

Financial Results for the six months ended June

Research and development expenses for the

six months ended June 30, 2023 were $3.8 million, compared to $4.3 million for the corresponding period in 2022. The reason

for the decrease in research and development expenses was primarily the result of a decrease in share-based compensation expenses, which

was more significant than the increase in the salary and related expenses as a result of the Company's recruitment of employees,

as well as the expansion of its research and development department.

Sales and marketing expenses for the six months

ended June 30, 2023, were $401,000 compared to $777,000 for the corresponding period in 2022. The decrease is attributable to

decreases in share-based compensation expenses and a reduction in marketing activities. The marketing department increased its efforts

in the first half of 2022 with respect to brand awareness and exploring go-to-market capabilities.

General and administrative expenses for the

six months ended June 30, 2023 were $2.1 million, compared to $2.9 million for the corresponding period in 2022. The decrease

resulted primarily from a decrease in share-based compensation expenses and a lower cost of director and officer insurance.

Finance income for the six months ended June

30, 2023, was $652,000, compared to $4.5 million for the corresponding period in 2022. The decrease in finance income resulted primarily

from the calculation of the fair market value of the Company's financial equity liabilities relating to its pre-initial public offering

(IPO) and IPO investors, in addition to the fluctuation in the U.S. dollar - New Israeli Shekel exchange rate during the first half

Finance expenses for the six months ended June

30, 2023 were $172,000, compared to $24,000 for the corresponding period in 2022. The increase in finance expenses resulted primarily

from the calculation of the fair market value of the Company's financial equity liabilities relating to its pre-IPO and IPO investors.

The net loss for the six months ended June

30, 2023 was $5.9 million, compared to a net loss of $3.5 million for the six months ended June 30, 2022.

Financial highlights for the three months

Research and development expenses for the

three months ended June 30, 2023 were $1.8 million, a decrease of $1 million compared to the second quarter of 2022. The decrease

was attributed to a decrease in share-based compensation expenses.

Sales and marketing expenses for the three

months ended June 30, 2023 were $233,000, a decrease of approximately $72,000 compared to the second quarter of 2022.

General and administrative expenses for the

three months ended June 30, 2023, were $1 million, a decrease of $400,000 compared to the second quarter of 2022. The decrease

resulted primarily from a decrease in share-based compensation expenses and a lower cost of director and officer insurance.

Finance income for the three months ended June

30,2023 was $284,000, compared to $2.4 million for the corresponding period in 2022. The decrease in finance income resulted primarily

from the calculation of the fair market value of the Company's financial equity liabilities relating to its pre-IPO and IPO investors,

in addition to the fluctuation in the U.S. dollar - New Israeli Shekel exchange rate during the first half of 2023.

Finance expenses for the three months ended June

30,2023 were $60,000, compared to $14,000 for the corresponding period in 2022.

Balance Sheet Highlights

Cash, cash equivalents and short-term bank

deposits were $8.9 million as of June 30, 2023, compared to $13.9 million as of December 31, 2022.

Financial liabilities at fair market value

totaled $438,000 as of June 30, 2023, compared to $368,000 as of December 31, 2022. The financial liabilities represent the fair market

value of the Company's equity liabilities to pre-IPO and IPO investors.

As of June 30, 2023, the Company's shareholders'

equity totaled $7.5 million, compared to shareholders' equity totaling $12.8 million as of December 31, 2022.

Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies has a clear mission to

revolutionize acute respiratory care through innovation. Our aim is to develop medical technologies and products that prevent the need

for mechanical ventilation. Empowering breathing without lungs, the flagship INSPIRATM ART500 is designed to boost blood oxygen saturation

levels in a matter of minutes, even as the patient remains awake. We strive to deliver blood circulation technology alongside AI driven

monitoring and analytics to create patient-centric and data-driven solutions that enhance patient outcome and improve hospital efficiency.

Through our continuous efforts, we aim to reshape the future of extracorporeal treatments to create a better healthcare experience for

patients around the world. The Company's products have not yet been tested or used in humans and have not been approved by any regulatory

For more information, please visit our corporate

website: https://inspira-technologies.com/

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements

pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations

of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ

materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it

discusses its belief that the third quarter is pivotal for the Company, the regulatory submission of the INSPIRATM ART100 to

the FDA via the 510(k) pathway, the timing thereof and expected clearance during the second half of 2023. These forward-looking statements

and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors

and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except

as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements

to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information

about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's

annual report on Form 20-F for the fiscal year ended December 31, 2022 filed with the SEC, which is available on the SEC's website,

MRK-ARS-057 Copyright 2018-2023 Inspira

UNAUDITED CONDENSED INTERIM STATEMENTS OF

(U.S. dollars in thousands)

UNAUDITED CONDENSED INTERIM STATEMENTS OF